Blocking TRPV4 Channel Restores Brain Fluid Clearance After Stroke
Inhibiting TRPV4 channels in mice restored glymphatic drainage, cut cerebral edema, and improved neurological recovery after ischemic stroke.
Summary
After ischemic stroke, brain swelling is a leading cause of death and disability. This study found that a protein channel called TRPV4 becomes overactive after stroke, triggering a cascade that disrupts the brain's glymphatic waste-clearance system — essentially clogging the brain's drain. Using a selective TRPV4 blocker (HC067047) administered directly into the ventricles of mice, researchers restored fluid drainage, reduced edema visible on MRI, and improved neurological function. The mechanism involves TRPV4 activating RhoA, which upregulates MMP9, an enzyme that degrades a critical anchoring protein (β-dystroglycan), causing the water channel AQP4 to mislocalize and disrupt glymphatic flow. This positions TRPV4 as a promising therapeutic target for stroke-related brain swelling.
Detailed Summary
Cerebral edema following ischemic stroke is a life-threatening complication with malignant cases carrying up to 80% mortality. Despite its severity, effective pharmacological strategies to prevent edema formation remain limited. This study, conducted at Nanfang Hospital, Southern Medical University, investigated whether inhibiting the TRPV4 ion channel could restore the brain's glymphatic drainage system and reduce post-stroke edema in a validated mouse model.
Researchers used male C57BL/6J mice subjected to 45 minutes of middle cerebral artery occlusion followed by reperfusion (MCAO/R), a well-established model of ischemic stroke. The TRPV4 inhibitor HC067047 (10 μM, 2 μL per dose) was delivered via pre-implanted lateral ventricle cannula at reperfusion onset and every 4 hours thereafter (4 total doses). Controls received vehicle. All primary molecular and imaging analyses were performed at 24 hours post-reperfusion.
Glymphatic function was assessed by injecting a 70 kDa fluorescent tracer (TMRE-dextran) into the cisterna magna and tracking its influx transcranially in living mice and in 100-μm brain sections. MCAO/R mice showed dramatically impaired tracer penetration into brain parenchyma compared to sham animals, and deep cervical lymph node fluorescence — a measure of efflux — was also markedly reduced. HC067047 treatment significantly restored both influx and efflux metrics, indicating improved glymphatic function. MRI-based quantification confirmed that HC067047-treated mice had substantially reduced cerebral edema volumes compared to vehicle-treated MCAO/R mice.
Mechanistically, the study found that TRPV4 expression was elevated in the ischemic penumbra after MCAO/R, alongside increased expression of RhoA and MMP9. β-dystroglycan (β-DG), the anchoring protein that tethers AQP4 water channels to astrocyte endfeet, was markedly downregulated — and AQP4 polarization (its concentration at perivascular endfeet) was disrupted. HC067047 treatment suppressed RhoA and MMP9 expression, partially restored β-DG levels, and partially rescued AQP4 perivascular polarization as quantified by immunofluorescence. Critically, selective MMP9 inhibition with SB-3CT also partially restored β-DG and AQP4 polarization, providing mechanistic validation of the TRPV4→RhoA→MMP9→β-DG→AQP4 depolarization axis.
Long-term behavioral testing showed that HC067047-treated animals had improved neurological scores compared to vehicle-treated MCAO/R mice, suggesting that restoring glymphatic function translates into meaningful functional recovery. The authors acknowledge that this is a preclinical mouse study with intracerebroventricular drug delivery — a route not currently used in human stroke care. Whether systemic or intranasal TRPV4 inhibition would achieve equivalent CNS concentrations remains untested, and translation to the clinical setting requires further study.
Key Findings
- HC067047 significantly restored glymphatic influx in MCAO/R mice as measured by transcranial and ex vivo fluorescent tracer penetration into brain parenchyma (qualitatively and quantitatively compared to vehicle controls)
- Deep cervical lymph node fluorescence — a marker of glymphatic efflux — was markedly reduced after MCAO/R and partially restored by HC067047 treatment
- MRI-quantified cerebral edema volume was significantly reduced in HC067047-treated MCAO/R mice versus vehicle-treated MCAO/R controls
- TRPV4 expression was significantly elevated in the ischemic penumbra at 24 h post-reperfusion compared to sham animals
- β-dystroglycan (β-DG) protein expression was markedly reduced and MMP9 and RhoA were significantly upregulated in MCAO/R mice; HC067047 suppressed MMP9 and RhoA and partially restored β-DG
- AQP4 perivascular polarization ratio was disrupted after MCAO/R and partially rescued by HC067047 treatment as confirmed by immunofluorescence
- Neurological function scores were significantly improved in HC067047-treated animals compared to vehicle-treated MCAO/R mice in long-term behavioral assessments
Methodology
Male C57BL/6J mice (8–10 weeks, 22–25 g) underwent 45-minute MCAO followed by reperfusion; HC067047 (10 μM, 2 μL) or vehicle was administered intracerebroventricularly at reperfusion and every 4 hours for 4 total doses. Glymphatic function was assessed by cisterna magna injection of 70 kDa TMRE-dextran with transcranial live imaging, ex vivo brain section fluorescence, and deep cervical lymph node analysis. Cerebral edema was quantified by MRI; protein expression was measured by Western blot and immunofluorescence; long-term outcomes used validated neurological scoring batteries. Laser speckle imaging confirmed MCAO success prior to group randomization.
Study Limitations
This study was conducted exclusively in male mice, limiting generalizability across sexes and to human stroke patients. Drug delivery was via intracerebroventricular cannulation, a route not feasible in routine clinical stroke care, and systemic or less invasive delivery methods were not tested. The study did not fully resolve whether AQP4 depolarization or total AQP4 expression changes are the primary driver of glymphatic dysfunction, and longer-term outcomes beyond the behavioral testing window were not reported.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.